Westfield Capital Management
UTHR icon

Westfield Capital Management’s United Therapeutics UTHR Stock Holding History

Westfield Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-541,235
Closed -$84.8M – 293
2015
Q4 		$84.8M Sell
541,235
-489,338
-47% -$71.2M 0.57% 60
2015
Q3 		$135M Buy
1,030,573
+11,920
+1% +$1.91M 0.96% 30
2015
Q2 		$177M Buy
1,018,653
+205,195
+25% +$36.9M 1.08% 20
2015
Q1 		$140M Buy
+813,458
New +$124M 0.81% 32

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Westfield Capital Management's UTHR Position: Q1 2016 in Review

Westfield Capital Management sold out of United Therapeutics (UTHR) in Q1 2016, closing a stake of 541,235 shares — an estimated $84.8M sold.

Westfield Capital Management first reported a position in UTHR in Q1 2015 and held it in 4 quarters. The position peaked at $177M in Q2 2015. 398 funds tracked by Wall St. Rank hold UTHR as of Q1 2016.

  • Westfield Capital Management reported no remaining United Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Westfield Capital Management sold 541,235 United Therapeutics shares in Q1 2016, an estimated $84.8M.
  • Westfield Capital Management first reported a position in United Therapeutics in Q1 2015 and held it in 4 quarters.
  • Westfield Capital Management's United Therapeutics position peaked at $177M in Q2 2015.
  • 398 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2016.

Based on Westfield Capital Management's 13F filing for Q1 2016, filed 13 May 2016.